Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through PepGen’s science-laden disclosures can feel like sequencing DNA—especially when trial data, cash runway, and orphan-drug incentives are scattered across hundreds of pages. If you’ve ever searched for PepGen insider trading Form 4 transactions or wondered where the latest PepGen quarterly earnings report 10-Q filing hides key burn-rate figures, you’re not alone.
Stock Titan’s AI turns that tangle into clarity. Our real-time engine monitors every submission to EDGAR, then delivers PepGen SEC filings explained simply. Need an at-a-glance view of dose-escalation safety from an 8-K? We tag it automatically. Curious about PepGen Form 4 insider transactions real-time before the next data readout? Instant alerts arrive the moment executives move shares. Our platform also provides concise breakdowns of:
- PepGen annual report 10-K simplified—cash runway, EDO platform milestones, risk factors.
- Understanding PepGen SEC documents with AI—auto-generated summaries and side-by-side year-over-year metrics.
- PepGen 8-K material events explained—trial halts, partnership updates, or FDA feedback distilled into plain English.
- PepGen proxy statement executive compensation—gene-therapy expertise isn’t cheap; see how leadership is paid.
The result? PepGen earnings report filing analysis you can actually use. Track PepGen executive stock transactions Form 4 to spot confidence signals, compare segment R&D spend across quarters, and export data straight into your models. Complex biotech filings no longer require advanced genetics degrees—just Stock Titan’s precise AI summaries and real-time filing feed.
PepGen Inc. schedules a passive ownership disclosure showing Suvretta Capital Management, Averill Master Fund and Aaron Cowen each report shared beneficial ownership of 300,000 shares of PepGen common stock, equal to 0.9% of the class. The filing states the reporting persons have shared voting and shared dispositive power over those shares, and that the securities are directly owned by advisory clients of Suvretta Capital Management. The report also states no reported holder is known to beneficially own more than 5% of the common stock and includes a disclaimer that reported persons disclaim beneficial ownership except for pecuniary interest. The filing affirms the securities were not acquired to influence control.
FAQ
What is the current stock price of PepGen (PEPG)?
What is the market cap of PepGen (PEPG)?
